SCHEMBL1138928

SCHEMBL1138928

[CH2]C[C@@H](O)CCc1ccc(F)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TAAR1 Q96RJ0 3/20 0.43
F2RL1 P55085 1/20 0.42
KCNH2 Q12809 1/20 0.41
TMEM97 Q5BJF2 1/20 0.41
SIGMAR1 Q99720 1/20 0.41
PTGER1 P34995 1/20 0.40
PTGFR P43088 1/20 0.40
PTGS1 P23219 1/20 0.39
PTGS2 P35354 1/20 0.39
MMP2 P08253 1/20 0.39
MMP9 P14780 1/20 0.39
MMP12 P39900 1/20 0.39
MMP13 P45452 1/20 0.39
MMP14 P50281 1/20 0.39
MAOB P27338 1/20 0.38
CYP19A1 P11511 2/20 0.37
KDM4E B2RXH2 1/20 0.37
MEN1 O00255 1/20 0.37
POLB P06746 1/20 0.37
MAPT P10636 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6692566 1.00 TAAR1 (0.43) TAAR1F2RL1KCNH2TMEM97SIGMAR1
SCHEMBL27547657 0.82 TAAR1 (0.45) TAAR1F2RL1KCNH2TMEM97SIGMAR1
SCHEMBL14005420 0.80 TAAR1 (0.54) TAAR1F2RL1PTGER1PTGFRPTGS1
SCHEMBL408931 0.80 TAAR1 (0.43) TAAR1F2RL1KCNH2TMEM97SIGMAR1
SCHEMBL4258881 0.80 CYP1A2 (0.43) TAAR1KCNH2PTGFRMMP2MMP9
SCHEMBL1139620 0.79 MMP12 (0.49) KCNH2MMP2MMP9MMP12MMP13
SCHEMBL7285509 0.79 MMP12 (0.49) KCNH2MMP2MMP9MMP12MMP13
SCHEMBL3938466 0.79 MMP12 (0.49) KCNH2MMP2MMP9MMP12MMP13
SCHEMBL14327418 0.79 TAAR1 (0.50) TAAR1F2RL1PTGS1PTGS2MAOB
SCHEMBL6692564 0.78 FFAR1 (0.42) TAAR1F2RL1PTGER1PTGFRPTGS1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1253160-B1 Electrophotographic encapsulated toner particles and method for making them CANON KK (JP) 2011-02-23 EP disclosed
US-7632618-B2 Polyhydroxyalkanoate-containing structure and manufacturing method thereof CANON KABUSHIKI KAISHA (JP) 2009-12-15 US disclosed
US-7615233-B2 Particulate construct comprising polyhydroxyalkanoate and method for producing it CANON KABUSHIKI KAISHA (JP) 2009-11-10 US disclosed
US-7527809-B2 Polyhydroxyalkanoate-containing magnetic structure, and manufacturing method and use thereof CANON KABUSHIKI KAISHA (JP) 2009-05-05 US disclosed
EP-1275378-B1 Particulate construct comprising polyhydroxyalkanoate and method for producing it CANON KK (JP) 2009-04-15 EP disclosed
US-20090061498-A1 POLYHYDROXYALKANOATE-CONTAINING STRUCTURE AND MANUFACTURING METHOD THEREOF CANON KABUSHIKI KAISHA (JP) 2009-03-05 US disclosed
US-20090029423-A1 METHOD FOR SEPARATING TARGET COMPONENT CANON KABUSHIKI KAISHA (JP) 2009-01-29 US disclosed
EP-1254930-B1 Particles for electrophoresis, a production method thereof and a display using the particles CANON KK (JP) 2008-06-18 EP disclosed
EP-1275728-B1 Polyhydroxyalkanoate-containing structure and manufacturing method thereof CANON KK (JP) 2008-06-04 EP disclosed
US-7186459-B2 Liposome coated with polyhydroxyalkanoate and production method thereof CANON KABUSHIKI KAISHA (JP) 2007-03-06 US disclosed
US-20030206330-A1 Particles for electrophoresis, a production method thereof and a display using the articles CANON KABUSHIKI KAISHA (JP) 2003-11-06 US disclosed
US-20030203987-A1 Pigment containing ink and production method thereof CANON KABUSHIKI KAISHA (JP) 2003-10-30 US disclosed
US-20030194443-A1 Particulate construct comprising polyhydroxyalkanoate and method for producing it CANON KABUSHIKI KAISHA (JP) 2003-10-16 US disclosed
US-20030113368-A1 Liposome coated with polyhydroxyalkanoate and production method thereof CANON KABUSHIKI KAISHA (JP) 2003-06-19 US disclosed
US-20030104302-A1 Construct and method for making it LASALLE BANK NATIONAL ASSOCIATION 2003-06-05 US disclosed
EP-1275728-A1 Polyhydroxyalkanoate-containing structure and manufacturing method thereof CANON KABUSHIKI KAISHA (JP) 2003-01-15 EP disclosed
EP-1275378-A2 Particulate construct comprising polyhydroxyalkanoate and method for producing it CANON KABUSHIKI KAISHA (JP) 2003-01-15 EP disclosed
EP-1256606-A2 Pigment containing ink and production method thereof CANON KABUSHIKI KAISHA (JP) 2002-11-13 EP disclosed
EP-1254930-A2 Particles for electrophoresis, a production method thereof and a display using the particles CANON KABUSHIKI KAISHA (JP) 2002-11-06 EP disclosed
EP-1253160-A2 Construct and method for making it CANON KABUSHIKI KAISHA (JP) 2002-10-30 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030194443-A1 Particulate construct comprising polyhydroxyalkanoate and method for producing it SQLE, FDFT1, CYP51A1 TAAR1 1068/4885F2RL1 1846/4885KCNH2 2721/4885
US-20030113368-A1 Liposome coated with polyhydroxyalkanoate and production method thereof LIPA, ABHD16A, LIPE TAAR1 1686/4885F2RL1 3090/4885KCNH2 841/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.